Chatbot Intervention Effects on Emotional Arousal in Anhedonia

July 7, 2026 updated by: Benjamin Becker, University of Electronic Science and Technology of China

Effects of a Chatbot-Based Intervention on Subjective Arousal and Neural Reactivity to Emotional Video Stimuli in Individuals With Anhedonia

The main aim of the present study is to investigate the effects of a Motivational Interviewing-based artificial intelligence chatbot on affective arousal in college students with elevated levels of depression and anhedonia by combining a randomized active-control intervention design with pre- and post-intervention emotional video task assessments during fMRI.

Study Overview

Detailed Description

Anhedonia represents a core characteristic of depression and is characterized by reduced experience of pleasure. It is closely related to decreased motivation, altered reward processing, changes in affective responsiveness, and alterations in intrinsic brain network function. Anhedonia is not specifically targeted by currently available pharmacological interventions. Initial evidence indicates that an increased willingness to change and implementation of change in daily life can alleviate anhedonia.

The present study aims to examine whether a Motivational Interviewing-based AI chatbot can lead to changes in affective arousal responses in college students with elevated anhedonia and depressive symptoms. Affective arousal is included because anhedonia may involve altered emotional reactivity and reduced subjective responses to affective stimuli, in addition to reduced pleasure. The emotional video task allows the study to assess subjective arousal responses and neural responses to positive, neutral, and negative affective stimuli. To this end, eligible participants with a total score of 22 or higher on the Snaith-Hamilton Pleasure Scale and a score of 14 or higher on the Beck Depression Inventory will undergo a randomized, between-subjects, active-control intervention study. Participants will be assigned to either a Motivational Interviewing-based chatbot group or an active control chatbot group for 1 week. Pre- and post-intervention assessments will include self-report questionnaires and an affective arousal video task during functional magnetic resonance imaging to examine psychological, behavioral, and neural effects of the intervention.

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Benjamin Becker, Dr
  • Phone Number: (852) 3917-5097
  • Email: bbecker@hku.hk

Study Locations

    • Sichuan
      • Chengdu, Sichuan, China
        • Recruiting
        • University of Electronic Science and Technology of China
        • Contact:
          • Benjamin Becker, Dr
          • Phone Number: (852) 3917-5097
          • Email: bbecker@hku.hk

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 18-40 years
  • Right-handed
  • Normal or corrected normal visual acuity
  • Participants must show elevated anhedonia and depressive symptoms at screening, defined as a total score of 22 or higher on the Snaith-Hamilton Pleasure Scale and a score of 14 or higher on the Beck Depression Inventory

Exclusion Criteria:

  • History of major central nervous system disorders, such as epilepsy, traumatic brain injury, stroke, or brain tumors.
  • History of severe mental illness, including schizophrenia spectrum disorders, bipolar disorder, or other psychotic disorders.
  • History of substance or alcohol use disorder or substance or alcohol misuse within the past 12 months that may affect study participation or outcome assessment.
  • Individuals currently at high risk of suicide, severe self-harm, or experiencing an acute psychiatric crisis.
  • Individuals who are currently using psychiatric medications or have undergone psychotherapy within the past 4 weeks that may significantly affect mood, motivation, or reward processing.
  • Severe vision or hearing impairments that cannot be corrected and would interfere with task performance.
  • Contraindications to MRI scanning, including metallic implants, pacemakers, severe claustrophobia, or other conditions incompatible with MRI.
  • Pregnancy or breastfeeding.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Motivational Interviewing-based AI chatbot group
Motivational Interviewing-based AI chatbot intervention
The experimental chatbot is designed to use principles of Motivational Interviewing to support participants in exploring their personal values, motivation for change, and daily behavioral goals related to pleasure, engagement, and reward-seeking. During the intervention period, participants will interact with the chatbot regularly through brief text-based conversations. The chatbot will provide empathic, non-judgmental responses, encourage reflection on current difficulties, and help participants identify small, feasible actions that may increase daily engagement and positive experiences. It will not provide diagnosis, crisis counseling, or medical treatment.
Active Comparator: Active control chatbot group
Active control nature-story chatbot intervention
Participants will interact with a chatbot matched in format and frequency of use. This chatbot will provide neutral nature-related stories or general natural history content. It will be designed to maintain participant engagement while avoiding therapeutic techniques, motivational interviewing strategies, behavioral activation guidance, or personalized mental health advice. This active control condition will help control for nonspecific effects of chatbot interaction, attention, expectancy, and digital engagement.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Subjective Affective Arousal in Response to Video Stimuli
Time Frame: Baseline before the first chatbot interaction and Week 1 after completion of the chatbot intervention.
Participants will view positive, neutral, and negative video stimuli before and after the intervention and report their subjective arousal after each video. Mean arousal ratings will be calculated separately for each emotional condition, and pre-to-post changes will be compared across positive, neutral, and negative video conditions
Baseline before the first chatbot interaction and Week 1 after completion of the chatbot intervention.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Activity in Brain Systems Supporting Affective Arousal Processing
Time Frame: Baseline before the first chatbot interaction and Week 1 after completion of the chatbot intervention.
Participants will undergo task-based BOLD fMRI while viewing positive, negative, and neutral emotional videos. Neural responses within predefined brain systems involved in arousal and valence processing will be estimated using a general linear model. Beta contrast estimates will then be derived for positive versus neutral, negative versus neutral, and positive versus negative conditions. These estimates will be used to evaluate changes from baseline to post-intervention.
Baseline before the first chatbot interaction and Week 1 after completion of the chatbot intervention.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 20, 2026

Primary Completion (Estimated)

June 30, 2028

Study Completion (Estimated)

December 31, 2028

Study Registration Dates

First Submitted

June 17, 2026

First Submitted That Met QC Criteria

June 22, 2026

First Posted (Actual)

June 26, 2026

Study Record Updates

Last Update Posted (Actual)

July 9, 2026

Last Update Submitted That Met QC Criteria

July 7, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • BAM_lab_MI_02

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Corresponding individual level data will be made available upon request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on MI Chatbot Interaction

3
Subscribe